Developing Treatments for Alzheimer’s Disease- ProMIS Neurosciences

© 2020 All Rights Reserved.

Renewed hope for Alzheimer’s cure

Alzheimer’s disease is a devastating disease that affects more than 25 million people. New understanding of what causes Alzheimer’s has renewed hope for a cure. ProMIS Neurosciences is developing therapies to treat ALS and Alzheimer’s by targeting a toxic protein in the brain. Furthermore, with no therapies currently available to stop the progression of these degenerative diseases. ProMIS has plans to initiate clinical trials in late 2019, offering real hope for an effective Alzheimer’s disease treatment.

ProMIS Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts. Finally, It is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF). Moreover, ProMIS is a development-stage biotechnology company focused on discovering and developing antibody therapeutics. Likewise, it is selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases. In particular, Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Core Science & Technology

The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. Thus, for over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins-toxic oliogmers (with over 300 publications and over 10,000 citations and 70 patent applications) and is one of several leading researchers in the field of toxic oligomers in neurodegenerative diseases.

For more information on ProMIS Neurosciences (PMN.TSE) please fill out the form below.

Alzheimer’s disease affects more than 25 million people. ProMIS is developing treatments for Alzheimer’s by targeting a toxic protein in the brain.

Request Investor Info